<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zagouri, F.</style></author><author><style face="normal" font="default" size="100%">Brandstetter, A.</style></author><author><style face="normal" font="default" size="100%">Moussiolis, D.</style></author><author><style face="normal" font="default" size="100%">Chrysikos, D.</style></author><author><style face="normal" font="default" size="100%">Dimitrakakis, C.</style></author><author><style face="normal" font="default" size="100%">Tsigginou, A.</style></author><author><style face="normal" font="default" size="100%">Marinopoulos, S.</style></author><author><style face="normal" font="default" size="100%">Zografos, G.C.</style></author><author><style face="normal" font="default" size="100%">Sergentanis, T.N.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.-A.</style></author><author><style face="normal" font="default" size="100%">Filipits, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Low protein expression of MET in ER-positive and HER2-positive breast cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style  face="normal" font="default" size="100%">breast cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">ER-positive</style></keyword><keyword><style  face="normal" font="default" size="100%">HER2- positive</style></keyword><keyword><style  face="normal" font="default" size="100%">MET</style></keyword><keyword><style  face="normal" font="default" size="100%">Prognosis</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84899675373&amp;partnerID=40&amp;md5=20aacd5e57a69e8b434e19bd036c7390</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">34</style></volume><pages><style face="normal" font="default" size="100%">1227 - 1231</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Aim: The mesenchymal-epithelial transition factor (MET) is a receptor tyrosine kinase that plays a key role in cell survival, growth, angiogenesis and metastasis. Because its expression is frequently altered in tumors, MET is currently under investigation as a potential target for anticancer therapy. The purpose of the present study was to determine the prognostic value of tumor MET expression levels in patients with estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-positive breast cancer, in order to strengthen the rationale for targeted therapy using MET inhibitors in this breast cancer subpopulation. Materials and Methods: We determined the expression of MET in formalin-fixed paraffin-embedded surgical specimens of ERand HER2-positive breast cancer by immunohistochemistry. Results: Comparisons of MET expression with clinical parameters, including survival of the patients, were performed with MET expression as a dichotomized variable classified as high or low. Out of 78 tumors, 3 (3.8%) showed high MET expression. The analysis examining the association between MET and survival did not yield any statistically significant result regarding overall survival or disease-free survival. Conclusion: ER- and HER2-positive breast carcinomas do not exhibit high MET expression. This null finding, the first to be reported in the literature, is of great importance, since it indicates that this sub-group population is not proper candidate for clinical trials with MET inhibitors.</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><notes><style face="normal" font="default" size="100%">Cited By :3Export Date: 21 February 2017</style></notes></record></records></xml>